Q1 FY27 results analysis · August 05, 2026

Biocon Q1 FY27 Results Analysis: PAT Surges 349%, Finance Costs Decline 23%

+53.4%PAT year on year, Rs. 136.80 Cr
Cofacto ResearchPublished August 05, 20262 min readNeutral read
Quick summary

Biocon Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 4,336.00 Cr (+10.00% YoY) and PAT growth of +53.40% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 05, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 4,336.00 Cr (+10.00% YoY)
PAT (Q1)Rs. 136.80 Cr (+53.40% YoY)
EBITDA margin19.54% (+11 bps YoY)
EPS (Q1)Rs. 0.87 (+234.60% YoY)
Market capRs. 68,781.18 Cr
CMPRs. 425.20

Quarter Snapshot

Biocon's Q1 FY27 results show strong growth in Biosimilars and Generics, with PAT attributable to owners surging 349% YoY and finance costs declining 23% from debt restructuring. However, the Services segment (Syngene) swung to a loss, dragging overall performance. The H2-weighted trajectory and new product launches provide catalysts, but Syngene's recovery remains the key swing factor.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 10.0% YoY to Rs.4,336 Cr
  • Biosimilars revenue increased 16.2% YoY to Rs.2,855.6 Cr
  • Generics revenue grew 20.5% YoY to Rs.759.7 Cr, with PBIT loss narrowing from -16.12% to -4.07%
  • PAT attributable to owners rose 349.4% YoY to Rs.141.1 Cr
  • Finance costs fell 23.0% YoY to Rs.213.2 Cr, reflecting debt restructuring benefits
  • Standalone PAT turned from a loss of Rs.8.3 Cr to a profit of Rs.52.2 Cr

Risk Factors

  • Services/CRDMO revenue declined 15.8% YoY and swung to a PBIT loss of Rs.5.7 Cr from a profit of Rs.101.3 Cr
  • Biosimilars PBIT margin eased to 6.00% from 6.78% a year ago, indicating pricing pressure from new product launches and competition
  • Generics segment remained loss-making at the PBIT level with a -4.07% margin
  • Syngene client concentration risk flagged as a single large molecule biologics client impacted results

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.